NCT02292069已完成1 期
Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fed Condition
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Area under curve (AUC)
研究概览
简要总结
This study is to assess the bioequivalence between Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg of Dr. Reddy's Laboratories Limited, India and CADUET® (amlodipine besylate and atorvastatin calcium) tablets 10mg/80mg of Pfizer Ireland Pharmaceuticals Dublin, Ireland in healthy, adult,human subjects under Fed conditions.
详细描述
Open label, randomized, two-treatment, two-period, two-sequence, oral bioequivalence study of Amlodipine besylate/Atorvastatin calcium Tablets 10mg/80mg under Fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects aged between 18 and 45 years (both inclusive).
- •Subjects' weight within normal range according to normal values for Body Mass Index (18.5 to 24.9 kg/m2) with minimum of 50 kg weight.
- •Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable reference range.
- •Subjects having normal 12-lead electrocardiogram (ECG).
- •Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period
- •Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
- •Subjects having negative alcohol breath test.
- •Subjects willing to adhere to the protocol requirements and to provide written informed consent.
排除标准
- •Hypersensitivity to Amlodipine and Atorvastatin or related class of drugs.
- •History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
- •Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
- •History or presence of significant alcoholism or drug abuse.
- •History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
- •History or presence of asthma, urticaria or other significant allergic reactions.
- •History or presence of significant gastric and/or duodenal ulceration.
- •History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- •History or presence of cancer.
- •Difficulty with donating blood.
- •Difficulty in swallowing solids like tablets or capsules.
- •Use of any prescribed or OTC medication during last two weeks prior to dosing in period
- •Major illness during 3 months before screening.
- •Participation in a drug research study within past 3 months.
- •Donation of blood in the past 3 months before screening.
- •Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing.
- •Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- •History or presence of significant easy bruising or bleeding.
- •History or presence of significant recent trauma.
研究组 & 干预措施
Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg
Experimental
Amlodipine besylate/Atorvastatin calcium tablets 10/80 mg of Dr. Reddys Laboratories Limited
干预措施: Amlodipine besylate/Atorvastatin calcium (Drug)
Caduet
Active Comparator
Caduet® 10/80 mg tablets of Pfizer, Ireland
干预措施: Amlodipine besylate/Atorvastatin calcium (Drug)
结局指标
主要结局
Area under curve (AUC)
时间窗: The post dose samples of 4.0 mL were drawn at 0.50, 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 7.00, 8.00, 10.00, 11.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours for Amlodipine assay
次要结局
- Area under curve (AUC)(post dose samples of 4.0mL were drawn at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.33, 3.67, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours for Atorvastatin assay)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting ConditionHealthyNCT02295046Dr. Reddy's Laboratories Limited80
已完成
1 期
Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed ConditionsHealthyNCT01645410Dr. Reddy's Laboratories Limited71
已完成
4 期
Double Blind Atorvastatin Amlodipine StudyAnginaNCT00159718Pfizer's Upjohn has merged with Mylan to form Viatris Inc.360
尚未招募
不适用
Bioeqivalence study of amlodipine valsartan 10/160 mg tabletBioequivalence study.IRCT20220209053979N5Alborz Darou24
已完成
4 期
Comparing Amlodipine/Atorvastatin Co-Administration To Amlodipine Alone In Patients With Hypertension And DyslipidemiaHypertensionHyperlipidemiaNCT00174330Pfizer's Upjohn has merged with Mylan to form Viatris Inc.330